Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.

[1]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  K. Michaëlsson,et al.  Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.

[3]  Peter C Austin,et al.  Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. , 2011, JAMA.

[4]  S. Ott,et al.  Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures , 2011, Osteoporosis International.

[5]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  Michael P. Kelly,et al.  Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. , 2010, The New England journal of medicine.

[7]  N. Napoli,et al.  Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies , 2010, Osteoporosis International.

[8]  R. Eastell,et al.  Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register‐Based National Cohort Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  A. Sayed-Noor,et al.  Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy , 2009, Clinical orthopaedics and related research.

[10]  Jeffrey R Curtis,et al.  Identification and Validation of Vertebral Compression Fractures Using Administrative Claims Data , 2009, Medical care.

[11]  P. Dayer,et al.  Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates , 2009, Drug safety.

[12]  J. Schneider.  Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. , 2009, Geriatrics.

[13]  B. Steele,et al.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.

[14]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[15]  Tet Sen Howe,et al.  More on atypical fractures of the femoral diaphysis. , 2008, The New England journal of medicine.

[16]  M. Seibel,et al.  More on atypical fractures of the femoral diaphysis. , 2008, New England Journal of Medicine.

[17]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[18]  D. Lorich,et al.  Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. , 2008, The New England journal of medicine.

[19]  T. Howe,et al.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? , 2008, Injury.

[20]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[21]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[22]  S. Silverman,et al.  Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study , 2006, Osteoporosis International.

[23]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  C. Kooperberg,et al.  Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.

[25]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[27]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[28]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[30]  D B Matchar,et al.  Incidence and occurrence of total (first-ever and recurrent) stroke. , 1999, Stroke.

[31]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[32]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[33]  M. Karagas,et al.  Fracture risk in the U.S. Medicare population. , 1999, Journal of clinical epidemiology.

[34]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[35]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[36]  W. Ray,et al.  Identification of fractures from computerized Medicare files. , 1992, Journal of clinical epidemiology.